Form 4: Artiva Biotherapeutics Chief Medical Officer Reports Stock Transactions
SEC Form 4 Filing
Thorsten Graef, Chief Medical Officer of Artiva Biotherapeutics, reports acquiring 60,000 shares of common stock and disposing of 80,000 shares.
Summary
- On February 26, 2025, Thorsten Graef, the Chief Medical Officer of Artiva Biotherapeutics, acquired 60,000 shares of common stock.
- The acquisition was through a restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan.
- On the same day, Mr. Graef disposed of 80,000 shares.
- Following these transactions, Mr. Graef directly owns 80,000 shares of Artiva Biotherapeutics.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may be of interest to shareholders as they provide insight into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date of stock acquisition and disposal. |
| 02/27/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.